EJNMMI reports最新文献

{"title":"PSMA-PET/CT response after metastasis-directed radiotherapy of bone oligometastases in prostate cancer.","authors":"Gabriel T Sheikh, Christian Trapp, Nina-Sophie Schmidt-Hegemann, Alexander Buchner, Christian G Stief, Marcus Unterrainer, Wolfgang G Kunz, Clemens C Cyran, Freba Grawe, Astrid Delker, Mathias J Zacherl, Adrien Holzgreve, Lena M Unterrainer, Matthias Brendel, Claus Belka, Minglun Li, Paul Rogowski","doi":"10.1186/s41824-024-00212-w","DOIUrl":"10.1186/s41824-024-00212-w","url":null,"abstract":"<p><strong>Objective: </strong>Bone metastases are very common in advanced prostate cancer and can sensitively be detected utilizing PSMA-PET/CT. Therefore, our goal was to evaluate the suitability of PSMA-PET/CT-guided metastasis-directed external beam radiotherapy (MDT) as treatment option for patients with biochemical recurrence and oligometastatic bone lesions.</p><p><strong>Materials & methods: </strong>We retrospectively examined 32 prostate cancer patients with biochemical recurrence and PSMA-positive oligometastatic disease limited to the bone (n = 1-3). A total of 49 bone lesions were treated with MDT. All patients received a post-radiotherapy PSMA-PET/CT-Scan. Changes in SUV_max, PSMA-positive tumor volume per lesion and PSA, as well as the correlation between the PET/CT-interval and SUV_max response were calculated.</p><p><strong>Results: </strong>MDT lead to a SUV_max decrease in 46/49 (94%) of the lesions. The median relative decline of SUV_max was 60.4%, respectively. Based on PSMA-positive lesion volume with a SUV cut-off of 4, 46/49 (94%) of lesions showed complete response, two (4%) partial response and one lesion (2%) was stable on PSMA-PET/CT after MDT. Most of the treated patients (56.3%) showed an initial PSA decline at three months and a PSA nadir of median 0.14 ng/ml after a median time of 3.6 months after MDT. The median relative PSA change at three months after MDT was 3.9%.</p><p><strong>Conclusion: </strong>MDT is a very effective treatment modality for prostate cancer bone oligometastases and lesion response to MDT can be assessed using the (semi-)quantitative parameters SUV_max and PSMA-positive lesion volume with established SUV cut-offs.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"25"},"PeriodicalIF":0.0,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11330950/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142001646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retrospective evaluation of the predictive value of tumour burden at baseline [⁶⁸ Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT.","authors":"Anni Gålne, Anna Sundlöv, Olof Enqvist, Katarina Sjögreen Gleisner, Erik Larsson, Elin Trägårdh","doi":"10.1186/s41824-024-00210-y","DOIUrl":"10.1186/s41824-024-00210-y","url":null,"abstract":"<p><strong>Purpose: </strong>There is a lack of validated imaging biomarkers for prediction of response to peptide receptor radionuclide therapy (PRRT). The primary objective was to evaluate if tumour burden at baseline PET/CT could predict treatment outcomes to PRRT with [¹⁷⁷Lu]Lu-DOTA-TATE. Secondary objectives were to evaluate if there was a correlation between tumour burden and mean tumour absorbed dose (AD) during first cycle, and if mean tumour AD or the relative change of tumour burden at first follow-up PET/CT could predict progression free survival (PFS) or overall survival (OS).</p><p><strong>Methods: </strong>Patients with gastroenteropancreatic neuroendocrine tumour (GEP-NET) treated with [¹⁷⁷Lu]Lu-DOTA-TATE PRRT were retrospectively included. Tumour burden was quantified from [⁶⁸ Ga]Ga-DOTA-TOC/TATE PET/CT-images at baseline and first follow-up and expressed as; whole-body somatostatin receptor expressing tumour volume (SRETVwb), total lesion somatostatin receptor expression (TLSREwb), largest tumour lesion diameter and highest SUVmax. The relative change of tumour burden was evaluated in three categories. Mean tumour AD was estimated from the first cycle of PRRT. PFS was defined as time from start of PRRT to radiological or clinical progression. OS was evaluated as time to death. Kaplan Meier survival curves and log-rank test were used to compare PFS and OS between different groups.</p><p><strong>Results: </strong>Thirty-one patients had a baseline PET/CT < 6 months before treatment and 25 had a follow-up examination. Median tumour burden was 132 ml (IQR 61-302) at baseline and 71 ml (IQR 36-278) at follow-up. Twenty-two patients had disease progression (median time to progression 17.2 months) and 9 patients had no disease progression (median follow-up 28.7 months). SRETVwb dichotomized by the median at baseline was not associated with longer PFS (p = 0.861) or OS (p = 0.937). Neither TLSREwb, largest tumour lesion or SUVmax showed significant predictive value. There was a moderately strong correlation, however, between SUVmax and mean tumour AD r = 0.705, p < 0.001, but no significant correlation between SRETVwb nor TLSREwb and mean tumour AD. An increase of SRETVwb, TLSREwb or largest tumour lesion at first follow-up PET/CT was significantly correlated with shorter PFS/OS.</p><p><strong>Conclusion: </strong>Tumour burden at baseline showed no predictive value of PFS/OS after PRRT in this small retrospective study. An increase of tumour burden was predictive of worse outcome.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"24"},"PeriodicalIF":0.0,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11306659/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141904134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary hepatic diffuse large B- cell lymphoma mimicking cholangiocarcinoma.","authors":"Taruna Yadav, Deepanksha Datta, Poonam Elhence, Vaibhav Varshney, Rajesh Kumar","doi":"10.1186/s41824-024-00215-7","DOIUrl":"10.1186/s41824-024-00215-7","url":null,"abstract":"<p><p>Primary lymphoma of liver is a rare malignancy with non-specific clinical features and tumor markers. The presentation and imaging features may be indistinguishable from other hepatic malignant lesions. Pathological diagnosis is the gold standard, and early detection is essential to choose the treatment modality. Here, we share an interesting case of Primary Diffuse Large B cell lymphoma of liver and its imaging findings on Computed tomography (CT), Magnetic Resonance Imaging (MRI) and F-18 FDG PET/CT.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"23"},"PeriodicalIF":0.0,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11291803/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141862052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"¹⁸F-FDG whole-body PET/CT for the evaluation of suspected native valve infective endocarditis.","authors":"Shihan Chen, Noah Ben-Ezra, Stephan Probst, Gad Abikhzer","doi":"10.1186/s41824-024-00207-7","DOIUrl":"10.1186/s41824-024-00207-7","url":null,"abstract":"<p><p>¹⁸F-FDG-PET/CT is indicated in the workup of patients with suspected infective endocarditis to detect intra-cardiac and disseminated infections, as well as its source. We present the case of a 66-year-old female patient known for recurrent diabetic foot infection, with equivocal TTE results and persistent MRSA bacteremia despite medical management. PET/CT revealed evidence of left foot osteomyelitis. Whole body PET/CT diagnosed native mitral valve infective endocarditis (IE) and right lower lobe segmental pulmonary artery uptake, consistent with septic pulmonary embolism (PE).</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"22"},"PeriodicalIF":0.0,"publicationDate":"2024-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11265061/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141736254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"FDG altered biodistribution in white adipose tissue, a rare entity: case report and review of the literature.","authors":"William Y Raynor, Stephen J Sozio, Jeffrey S Kempf","doi":"10.1186/s41824-024-00209-5","DOIUrl":"10.1186/s41824-024-00209-5","url":null,"abstract":"<p><strong>Purpose: </strong>Altered ¹⁸F-fluorodeoxyglucose (FDG) biodistribution due to patient factors such as exercise and inadequate fasting are well established causes of limited diagnostic efficacy. In addition, medications such as G-CSF are known to affect uptake of FDG by bone marrow and spleen. In this study, we present a case of increased white adipose uptake in a pediatric lymphoma patient who recently received high dose dexamethasone and review the relevant literature regarding this rare and poorly understood pattern of altered FDG biodistribution.</p><p><strong>Methods: </strong>A 14-year-old male patient diagnosed with B-cell lymphoblastic lymphoma underwent FDG-PET/CT for restaging shortly after completing an induction chemotherapy regimen. Images revealed diffuse FDG uptake localizing to white adipose tissue, attributed to the 29-day course of dexamethasone which was completed two days prior. A diagnostically adequate study with relative normalization of FDG biodistribution was obtained seven days later.</p><p><strong>Results: </strong>In our review of the literature, diffuse FDG uptake by white fat is a rare occurrence and has only been reported by a few case reports and early observational studies. In addition to patients receiving corticosteroids, other cases of medication-induced adipose remodeling such as patients receiving highly active antiretroviral therapy have been documented with similar patterns of increased white adipose tissue activity.</p><p><strong>Conclusion: </strong>Corticosteroid-induced white fat uptake of FDG is a rare phenomenon that can limit diagnostic accuracy of FDG-PET/CT and necessitate repeat imaging. Current evidence suggests that a wait period of at least one week after discontinuation of corticosteroids is sufficient to allow for decreased white fat uptake and increased diagnostic accuracy.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"21"},"PeriodicalIF":0.0,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11247065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Presentation of metastatic carotid body paraganglioma on F-18 FDG PET/CT: a rare disease.","authors":"Mehul Dulet, Vaibhav Trivedi, Deepanksha Datta, Poonam Elhence, Rajesh Kumar","doi":"10.1186/s41824-024-00211-x","DOIUrl":"10.1186/s41824-024-00211-x","url":null,"abstract":"<p><p>Carotid body paraganglioma is a slow growing tumor of head and neck region. It can rarely be malignant in nature which is characterized by distant metastases on anatomical imaging. We share an interesting presentation of a malignant carotid body on F-18 FDG PET/CT in form of liver and skeletal metastases.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"20"},"PeriodicalIF":0.0,"publicationDate":"2024-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11228009/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141556446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Regional changes in brain metabolism during the progression of mild cognitive impairment: a longitudinal study based on radiomics.","authors":"Xuxu Mu, Caozhe Cui, Jue Liao, Zhifang Wu, Lingzhi Hu","doi":"10.1186/s41824-024-00206-8","DOIUrl":"10.1186/s41824-024-00206-8","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to establish radiomics models based on positron emission tomography (PET) images to longitudinally predict transition from mild cognitive impairment (MCI) to Alzheimer's disease (AD).</p><p><strong>Methods: </strong>In our study, 278 MCI patients from the ADNI database were analyzed, where 60 transitioned to AD (pMCI) and 218 remained stable (sMCI) over 48 months. Patients were divided into a training set (n = 222) and a validation set (n = 56). We first employed voxel-based analysis of 18F-FDG PET images to identify brain regions that present significant SUV difference between pMCI and sMCI groups. Radiomic features were extracted from these regions, key features were selected, and predictive models were developed for individual and combined brain regions. The models' effectiveness was evaluated using metrics like AUC to determine the most accurate predictive model for MCI progression.</p><p><strong>Results: </strong>Voxel-based analysis revealed four brain regions implicated in the progression from MCI to AD. These include ROI1 within the Temporal lobe, ROI2 and ROI3 in the Thalamus, and ROI4 in the Limbic system. Among the predictive models developed for these individual regions, the model utilizing ROI4 demonstrated superior predictive accuracy. In the training set, the AUC for the ROI4 model was 0.803 (95% CI 0.736, 0.865), and in the validation set, it achieved an AUC of 0.733 (95% CI 0.559, 0.893). Conversely, the model based on ROI3 showed the lowest performance, with an AUC of 0.75 (95% CI 0.685, 0.809). Notably, the comprehensive model encompassing all identified regions (ROI total) outperformed the single-region models, achieving an AUC of 0.884 (95% CI 0.845, 0.921) in the training set and 0.816 (95% CI 0.705, 0.909) in the validation set, indicating significantly enhanced predictive capability for MCI progression to AD.</p><p><strong>Conclusion: </strong>Our findings underscore the Limbic system as the brain region most closely associated with the progression from MCI to AD. Importantly, our study demonstrates that a PET brain radiomics model encompassing multiple brain regions (ROI total) significantly outperforms models based on single brain regions. This comprehensive approach more accurately identifies MCI patients at high risk of progressing to AD, offering valuable insights for non-invasive diagnostics and facilitating early and timely interventions in clinical settings.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"19"},"PeriodicalIF":0.0,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11214937/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474416","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increased [⁶⁸Ga]Ga-SST uptake in the uncinate pancreatic process in new digital PET/CT machine and potential association with clinical and histologic factors in NET patients.","authors":"Maria Firsova, Giorgio Treglia, Christine Sempoux, Clarisse Dromain, John O Prior, Niklaus Schaefer, Sarah Boughdad","doi":"10.1186/s41824-024-00203-x","DOIUrl":"10.1186/s41824-024-00203-x","url":null,"abstract":"<p><strong>Introduction: </strong>A physiological increase in the uptake of [⁶⁸Ga]Ga-labeled somatostatin analogues ([⁶⁸Ga]Ga-SST) PET tracers has been reported in the uncinate pancreatic process (UP) and might be even higher in latest generation of PET/CT scanners and might be falsely interpreted as NET. We aimed to investigate the uptake of UP in a large population of NET patients who underwent [⁶⁸Ga]Ga-SST PET/CT with digital SiPM detectors. We also explored potential associations between UP uptake and various clinical, imaging, and pathological factors routinely assessed in NET patients.</p><p><strong>Methods: </strong>We analyzed all consecutive NET patients from July 2018 to June 2022 in this retrospective, single-center study. All patients underwent a [⁶⁸Ga]Ga-SST PET/CT scan on a digital SiPM PET/CT scanner. On visual analysis, we distinguished between normal linear and homogenous UP uptake or abnormal if otherwise. We compared SUV_max/mean in patients with normal UP uptake to those with abnormal UP uptake with suspicious NET lesions on contrast-enhanced CT (ce-CT) and according to the site of the primary NET (pancreatic NET vs. other), patient gender (female vs. male) and tumor grade (grade 1-2 vs. 3) using a Mann-Whitney test. We also assessed the correlation between SUV_max/mean values in UP with patients' age, primary NET Ki-67 counting, and its SUV_max/mean, TLA and MTV values.</p><p><strong>Results: </strong>We included 131 NET patients with a total of 34 [⁶⁸Ga]Ga-DOTATATE PET/CT and 113 [⁶⁸Ga]Ga-DOTATOC PET/CT scans. An abnormal UP uptake was seen in 32 patients with 65.7% of suspicious NET lesion or extrinsic compression on morphological imaging. Normal UP uptake SUV_max/mean were measured in 115 [⁶⁸Ga]Ga-SST scans (78.2%) with normal UP uptake and without suspicious lesion on morphological imaging. We found an average SUV_max of 12.3 ± 4.1 for [⁶⁸Ga]Ga-DOTATATE and 19.8 ± 9.8 g/ml for [⁶⁸Ga]Ga-DOTATOC, hence higher than those reported in the literature [SUVmax 5 ± 1.6 to 12.6 ± 2.2 g/ml] with significant difference with abnormal UP uptake and between both PET tracers (both p < 0.01). Significant results were a higher UP uptake on [⁶⁸Ga]Ga-DOTATOC in male patients (p = 0.02) and significant associations between UP uptake on [⁶⁸Ga]Ga-DOTATOC and SUV_max/mean of the primary tumor (ρ [0.337-0.363]; p [0.01-0.02]).</p><p><strong>Conclusion: </strong>We confirmed a higher and very frequent UP uptake in latest SiPM-detector [⁶⁸Ga]Ga-SST PET/CT with an even higher uptake in patients that had [⁶⁸Ga]Ga-DOTATOC PET/CT. SUV_mean/max were significantly higher in abnormal UP uptake but there were overlaps with UP SUV values for both [⁶⁸Ga]Ga-SST and a correlation to morphological imaging is crucial. Besides, significant ass","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"18"},"PeriodicalIF":0.0,"publicationDate":"2024-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11194230/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141444047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3D-visualization of segmented contacts of directional deep brain stimulation electrodes via registration and fusion of CT and FDCT.","authors":"Fadil Al-Jaberi, Matthias Moeskes, Martin Skalej, Melanie Fachet, Christoph Hoeschen","doi":"10.1186/s41824-024-00208-6","DOIUrl":"10.1186/s41824-024-00208-6","url":null,"abstract":"<p><strong>Objectives: </strong>3D-visualization of the segmented contacts of directional deep brain stimulation (DBS) electrodes is desirable since knowledge about the position of every segmented contact could shorten the timespan for electrode programming. CT cannot yield images fitting that purpose whereas highly resolved flat detector computed tomography (FDCT) can accurately image the inner structure of the electrode. This study aims to demonstrate the applicability of image fusion of highly resolved FDCT and CT to produce highly resolved images that preserve anatomical context for subsequent fusion to preoperative MRI for eventually displaying segmented contactswithin anatomical context in future studies.</p><p><strong>Material and methods: </strong>Retrospectively collected datasets from 15 patients who underwent bilateral directional DBS electrode implantation were used. Subsequently, after image analysis, a semi-automated 3D-registration of CT and highly resolved FDCT followed by image fusion was performed. The registration accuracy was assessed by computing the target registration error.</p><p><strong>Results: </strong>Our work demonstrated the feasibility of highly resolved FDCT to visualize segmented electrode contacts in 3D. Semiautomatic image registration to CT was successfully implemented in all cases. Qualitative evaluation by two experts revealed good alignment regarding intracranial osseous structures. Additionally, the average for the mean of the target registration error over all patients, based on the assessments of two raters, was computed to be 4.16 mm.</p><p><strong>Conclusion: </strong>Our work demonstrated the applicability of image fusion of highly resolved FDCT to CT for a potential workflow regarding subsequent fusion to MRI in the future to put the electrodes in an anatomical context.</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"17"},"PeriodicalIF":0.0,"publicationDate":"2024-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11286893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141319490","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to COVID-19 vaccination imaged by PD-L1 PET scanning.","authors":"Michael P MacManus, Tim Akhurst, Sharon R Lewin, Fiona Hegi-Johnson","doi":"10.1186/s41824-024-00196-7","DOIUrl":"10.1186/s41824-024-00196-7","url":null,"abstract":"<p><strong>Background: </strong>During a phase 0 clinical trial of an investigational programmed cell death ligand-1 (PD-L1) PET tracer in patients with non-small cell lung cancer (NSCLC), three patients received booster doses of COVID-19 vaccines before PD-L1 imaging.</p><p><strong>Methods: </strong>Five patients underwent whole-body PET/CT imaging with a novel PD-L1 tracer, constructed by attaching ⁸⁹Zr to the anti PD-L1 antibody durvalumab. Intramuscular (deltoid) booster doses of mRNA BNT162b2 COVID-19 mRNA vaccine were coincidentally given to three patients in the month before PD-L1 tracer injection.</p><p><strong>Results: </strong>Two recently-vaccinated patients, in remission of NSCLC and receiving non-immunosuppressive cancer therapies (immunotherapy and tyrosine kinase inhibitor respectively), showed increasing PD-L1 tracer uptake in ipsilateral axillary lymph nodes. No asymmetric nodal uptake was seen in a third recently-vaccinated patient who was receiving immunosuppressive chemotherapy, or in two patients not recently-vaccinated.</p><p><strong>Conclusion: </strong>Immune response to mRNA BNT162b2 vaccination may involve regulation by PD-L1 positive immune cells in local draining lymph nodes in immunocompetent patients.</p><p><strong>Trial registration: </strong>This trial was registered with the Australian New Zealand Clinical Trials Registry. Registration number ACTRN12621000171819. Date of Trial Registration 8/2/2021. Date of enrolment of 1st patient 11/4/2021. URL of trial registry record: https://www.australianclinicaltrials.gov.au/anzctr/trial/ACTRN12621000171819 .</p>","PeriodicalId":519909,"journal":{"name":"EJNMMI reports","volume":"8 1","pages":"16"},"PeriodicalIF":0.0,"publicationDate":"2024-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11156812/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141285818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}